Latest Neurizon Therapeutics News & Updates

See the latest news and media coverage for Neurizon. We track all announcements, press releases, and industry mentions in real time, all in one place.

Neurizon Therapeutics (Neurizon)

Biotechnology company developing treatments for neurodegenerative diseases

neurizon.com

Headquarters: Melbourne, Australia
Company type: Public company
Number of employees: 10–12
Industry: Pharmaceuticals

Last updated October 28

Latest news about Neurizon Therapeutics (Neurizon)

In short: Neurizon fully enrolled ALS trial, got FDA single-trial path, halted for capital raising

Company announcements

October 28 Neurizon

Neurizon requests trading halt pending capital raising announcement

Trading stops on October 29, 2026, until November 2 or disclosure of financing details.

October 27 Neurizon

Neurizon releases quarterly update and Appendix 4C on October 28 2026

The company released its Appendix 4C statement alongside a quarterly update to shareholders on October 28 2026 at midnight.

October 5 Neurizon

Neurizon FDA feedback indicates HEALEY trial potentially registrational

The FDA confirmed that the HEALEY Regimen I may serve as a single registrational study for a traditional NDA if results meet efficacy standards.

September 30 Neurizon

Neurizon announces Dr Chris Bremer as new CEO

Bremer leads the Phase 2/3 HEALEY trial for NUZ-001 in ALS, with top-line results expected in late Q2 2027, and appoints Sergio Duchini as Non-Executive Chairman.

Media coverage

October 27 BiotechDispatch

FDA gives Neurizon a faster route to approval as its pivotal ALS readout nears

Neurizon Therapeutics has finished enrolling its pivotal ALS trial ahead of schedule. The US Food and Drug Administration has also told the Melbourne company that...

October 5 BioWorld

Neurizon eyes registrational path as pivotal ALS readout nears

Neurizon Therapeutics Ltd. has advanced NUZ-001 (monepantel) from a 12-patient proof-of-concept study into a fully enrolled, 250-patient amyotrophic lateral sclerosis (ALS) trial that the U.S...

September 8 AdelaideNow

Key US health body funds expanded access initiative for ALS patients

The Healey & AMG Center for ALS has been awarded a multimillion-dollar US government grant to fund an expanded access program that could give up...

April 14 Australian Financial Review

Biotech Neurizon launches $11.3m shortfall auction after rights issue

The deal is aiming to cover the shortfall from a $17.1 million pro rata non-renounceable entitlement offer announced on December 23.

Never miss news about Neurizon

Track Neurizon and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Neurizon competitors & trending companies

Browse news for competitors to Neurizon and other trending companies.